453
Participants
Start Date
November 8, 2021
Primary Completion Date
March 27, 2023
Study Completion Date
April 20, 2023
fezolinetant
oral
placebo
oral
Site NO47001, Hamar
Site BE32005, Tienen
Site HU36002, Debrecen
Site DK45002, Odense
Site HU36004, Kecskemét
Site DK45004, Vejle
Site DK45005, Arhus C
Site HU36001, Szekesfeherver
Site ES34005, Centellas
Site DK45003, Gandrup
Site DE49002, Leipzig
Site IT39002, Bologna
Site DE49008, Muechen
Site FR33003, La Rochelle
Site SE46003, Stockholm
Site DE49006, Schwerin
Site DE49004, Hamburg
Site DE49005, Hamburg
Site IT39006, Pavia
Site ES34001, Madrid
Site ES34002, Alcobendas
Site ES34003, Leganés
Site TR90002, Konak
Site TR90008, Izmir
Site CZ42010, České Budějovice
Site CZ42007, Tábor
Site FR33001, Nantes
Site CZ42011, Náchod
Site PL48012, Skorzewo
Site CA15008, Brampton
Site CA15010, London
Site CA15003, Sarnia
Site CA15012, Montreal
Site CA15014, Québec
Site CA15011, Saint Charles Borromeee
Site CA15001, Sherbrooke
Site CA15005, Victoriaville
Site CA15002, Québec
Site CA15009, Québec
Site CA15007, Québec
Site CZ42002, Vodňany
Site CZ42008, Brno
Site CZ42005, Cheb
Site CZ42009, Hradec Králové
Site CZ42003, Olomouc
Site CZ42004, Písek
Site CZ42006, Prague
Site FI35801, Kuopio
Site FI35803, Oulu
Site NL31001, Beek
Site NL31004, Rotterdam
Site PL48001, Szczecin
Site PL48003, Bialystok
Site PL48013, Bydgoszcz
Site PL48006, Katowice
Site PL48011, Katowice
Site PL48004, Katowice
Site PL48007, Lublin
Site PL48009, Siedice
Site PL48017, Skierniewice
Site PL48010, Zamość
Site SE46004, Qerebro
Site SE46002, Uppsala
Site TR90001, Ankara
Site GB44007, Corby
Site GB44004, Shipley
Site GB44002, Coventry
Site GB44006, Northwood
Site GB44003, Orpington
Astellas Pharma Global Development, Inc.
INDUSTRY